Dietary Fiber-Induced Microbial Short Chain Fatty Acids Suppress ILC2-Dependent Airway Inflammation

Gavin Lewis(Janssen (United States)), Bowen Wang(University of Southern California), Pedram Shafiei-Jahani(University of Southern California), Benjamin P. Hurrell(University of Southern California), Homayon Banie(Janssen (United States)), German R. Aleman Muench(Janssen (United States)), Hadi Maazi(University of Southern California), Doumet Georges Helou(University of Southern California), Emily Howard(University of Southern California), Lauriane Galle-Treger(University of Southern California), Richard Lo(University of Southern California), Swetha Santosh(University of Southern California), Andrew Baltus(Janssen (United States)), Gerold Bongers(Janssen (United States)), Lani San-Mateo(Janssen (United States)), Frank D. Gilliland(University of Southern California), Virender K. Rehan(Harbor–UCLA Medical Center), Pejman Soroosh(Janssen (United States)), Omid Akbari(University of Southern California)
Frontiers in Immunology
September 18, 2019
Cited by 151Open Access
Full Text

Abstract

Group 2 Innate lymphoid cells (ILC2) contribute significantly to allergic inflammation. However, the role of microbiota on ILC2s remains to be unraveled. Here we show that short chain fatty acids (SCFAs), such as butyrate, derived from fermentation of dietary fibers by the gut microbiota inhibit pulmonary ILC2 functions and subsequent development of airway hyperreactivity (AHR). We further show that SCFAs modulate GATA3, oxidative phosphorylation, and glycolytic metabolic pathways in pulmonary ILC2s. The observed phenotype is associated with increased IL-17a secretion by lung ILC2s and linked to enhanced neutrophil recruitment to the airways. Finally, we show that butyrate-producing gut bacteria in germ-free mice effectively suppress ILC2-driven AHR. Collectively, our results demonstrate a previously unrecognized role for microbial-derived SCFAs on pulmonary ILC2s in the context of AHR. The data suggest strategies aimed at modulating metabolomics and microbiota in the gut, not only to treat, but to prevent lung inflammation and asthma.


Related Papers

No related papers found

Powered by citation graph analysis